A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Concurrent chemoradiotherapy (CCRT) is considered the treatment option for locally advanced pancreatic cancer, but accompanying gastrointestinal toxicities are the most common complication. With the introduction of three-dimensional conformal radiotherapy (3-D CRT) and intensity-modulated radiotherapy (IMRT), CCRT-related adverse events are expected to diminish. Here, we evaluated the benefits of radiation modalities by comparing gastrointestinal toxicities between 3-D CRT and IMRT. Methods: Patients who received CCRT between July 2010 and June 2012 in Severance Hospital, Yonsei University College of Medicine, were enrolled prospectively. The patients underwent upper endoscopy before and 1 month after CCRT. Results: A total of 84 patients were enrolled during the study period. The radiotherapy modalities delivered included 3D-CRT (n=40) and IMRT (n=44). The median follow-up period from the start of CCRT was 10.6 months (range, 3.8 to 29.9 months). The symptoms of dyspepsia, nausea/vomiting, and diarrhea did not differ between the groups. Upper endoscopy revealed significantly more gastroduodenal ulcers in the 3-D CRT group (p=0.003). The modality of radiotherapy (3D-CRT; odds ratio [OR], 11.67; p=0.011) and tumor location (body of pancreas; OR, 11.06; p=0.009) were risk factors for gastrointestinal toxicities. Conclusions: IMRT is associated with significantly fewer gastroduodenal injuries among patients treated with CCRT for pancreatic cancer.
Abstract
Background/Aims: Concurrent chemoradiotherapy (CCRT) is considered the treatment option for locally advanced pancreatic cancer, but accompanying gastrointestinal toxicities are the most common complication. With the introduction of three-dimensional conformal radiotherapy (3-D CRT) and intensity-modulated radiotherapy (IMRT), CCRT-related adverse events are expected to diminish. Here, we evaluated the benefits of radiation modalities by comparing gastrointestinal toxicities between 3-D CRT and IMRT. Methods: Patients who received CCRT between July 2010 and June 2012 in Severance Hospital, Yonsei University College of Medicine, were enrolled prospectively. The patients underwent upper endoscopy before and 1 month after CCRT. Results: A total of 84 patients were enrolled during the study period. The radiotherapy modalities delivered included 3D-CRT (n=40) and IMRT (n=44). The median follow-up period from the start of CCRT was 10.6 months (range, 3.8 to 29.9 months). The symptoms of dyspepsia, nausea/vomiting, and diarrhea did not differ between the groups. Upper endoscopy revealed significantly more gastroduodenal ulcers in the 3-D CRT group (p=0.003). The modality of radiotherapy (3D-CRT; odds ratio [OR], 11.67; p=0.011) and tumor location (body of pancreas; OR, 11.06; p=0.009) were risk factors for gastrointestinal toxicities. Conclusions: IMRT is associated with significantly fewer gastroduodenal injuries among patients treated with CCRT for pancreatic cancer.
참고문헌 (33)
- Huguet F, "Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review", J Clin Oncol, 27, pp.2269~2277 (2009)
- Loehrer PJ Sr, "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial", J Clin Oncol, 29, pp.4105~4112 (2011)
- Evans DB, "Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head", J Clin Oncol, 26, pp.3496~3502 (2008)
- Le Scodan R, "Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review", Ann Oncol, 20, pp.1387~1396 (2009)
- Brunner TB, "The role of radiotherapy in multimodal treatment of pancreatic carcinoma", Radiat Oncol, 5, pp.64~ (2010)
- Palta M, "Role of radiation therapy in patients with resectable pancreatic cancer", Oncology, 25(727), pp.715~721 (2011)
- Wilkowski R, "Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose", JOP, 6, pp.216~230 (2005)
- Varadhachary GR, "Preoperative therapies for resectable and borderline resectable pancreatic cancer", J Gastrointest Oncol, 2, pp.136~142 (2011)
- 이경주, "Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer", Gut and Liver, 7(1), pp.106~111 (2013), 거트앤리버 발행위원회
- Nakamura A, "Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy", Int J Radiat Oncol Biol Phys, 84, pp.369~375 (2012)
- Kavanagh BD, "Radiation dose-volume effects in the stomach and small bowel", Int J Radiat Oncol Biol Phys, 76(3), pp.S101~S107 (2010)
- Yovino S, "Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers", Int J Radiat Oncol Biol Phys, 79, pp.158~162 (2011)
- Kataria T, "Intensity modulated radiotherapy in abdominal malignancies: our experience in reducing the dose to normal structures as compared to the gross tumor", J Cancer Res Ther, 2, pp.161~165 (2006)
- Taylor R, "Comparison of radiation treatment delivery for pancreatic cancer: linac intensity-modulated radiotherapy versus helical tomotherapy", J Med Imaging Radiat Oncol, 56, pp.332~337 (2012)
- Mackie TR, "Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy", Med Phys, 20, pp.1709~1719 (1993)
- Callery MP, "Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement", Ann Surg Oncol, 16, pp.1727~1733 (2009)
- Combs SE, "Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes", Radiat Oncol, 1, pp.23~ (2006)
- Koom WS, "CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy", Int J Radiat Oncol Biol Phys, 73, pp.1148~1154 (2009)
- DeCosse JJ, "The natural history and management of radiation induced injury of the gastrointestinal tract", Ann Surg, 170, pp.369~384 (1969)
- Moertel CG, "Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group", Cancer, 48, pp.1705~1710 (1981)
- Springett GM, "Borderline resectable pancreatic cancer:on the edge of survival", Cancer Control, 15, pp.295~307 (2008)
- Belli C, "Neoadjuvant therapy in resectable pancreatic cancer: a critical review", Cancer Treat Rev, 39, pp.518~524 (2013)
- Strobel O, "Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer", Surgery, 152(3 Suppl 1), pp.S33~S42 (2012)
- Papalezova KT, "Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?", J Surg Oncol, 106, pp.111~118 (2012)
- Dobelbower RR Jr, "The radiotherapy of pancreatic cancer", Semin Oncol, 6, pp.378~389 (1979)
- Wang F, "The role of radiotherapy in management of pancreatic cancer", J Gastrointest Oncol, 2, pp.157~167 (2011)
- Combs SE, "Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer: outcome analysis and comparison with a 3D-treated patient cohort", Strahlenther Onkol, 189, pp.738~744 (2013)
- Poppe MM, "A comparison of helical intensity-modulated radiotherapy, intensitymodulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer", Med Dosim, 36, pp.351~357 (2011)
- Chang JS, "High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer", Int J Radiat Oncol Biol Phys, 83, pp.1448~1454 (2012)
- Chung HW, "A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer", Int J Radiat Oncol Biol Phys, 60, pp.1494~1501 (2004)
- Cho IR, "Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer", Pancreatology, 13, pp.539~543 (2013)
- Zhu CP, "Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis", Radiother Oncol, 99, pp.108~113 (2011)
- Huang J, "Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer", Radiother Oncol, 99, pp.114~119 (2011)